Erratum to: Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson's disease patients (vol 9, pg 39, 2017)

Author(s):
Bedarf, Janis R.; Hildebrand, Falk; Coelho, Luis P.; Sunagawa, Shinichi; Bahram, Mohammad; Goeser, Felix; Bork, Peer; Wüllner, Ullrich

Publication Date:
2017-06-29

Permanent Link:
https://doi.org/10.3929/ethz-b-000191807

Originally published in:
Genome Medicine 9, http://doi.org/10.1186/s13073-017-0451-z

Rights / License:
Creative Commons Attribution 4.0 International
Erratum to: Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients

J. R. Bedarf 1,2†, F. Hildebrand 4†, L. P. Coelho 4, S. Sunagawa 4,5, M. Bahram 9,10, F. Goeser 3,11, P. Bork 4,6,7,8,13* and U. Wüllner 1,2,12*

Erratum
Following the publication of this article [1], it was brought to our attention that due to miscommunications in the production process, Fig. 1 labels were missing and Fig. 4 labelling was incorrect in the original online version.

The errors:

1. The x and y axis were accidentally omitted from Fig. 1c and d, as well as the key from 1b. The corrected Fig. 1 is presented below:

2. MaoB hemmer was erroneously used instead of the English term MaoB inhibitor in Fig. 4. The corrected Fig. 4 is presented below:

The above errors have been corrected in the original version of this article [1].

Author details
1Department of Neurology, University of Bonn, Bonn, Germany. 2German Centre for neurodegenerative disease research (DZNE), Bonn, Germany.
3Department of Internal Medicine I, University of Bonn, Bonn, Germany.
4European Molecular Biology Laboratory, EMBL, Heidelberg, Germany. 5ETH Zurich, Institute of Microbiology, Vladimir-Prelog-1-5/10, 8093 Zurich, Switzerland.
6Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg, Germany.
7Max Delbrück Centre for Molecular Medicine (MDC), 13125 Berlin, Germany. 8Department of Bioinformatics, University of Würzburg, 97074 Würzburg, Germany.
9Evolutionary Biology Centre, Uppsala University, Norbyva gen 18D, 75236 Uppsala, Sweden.
10Institute of Ecology and Earth Sciences, University of Tartu, 40 Lai St., 51005 Tartu, Estonia.
11German Center for Infection Research (DNZIF), Bonn-Cologne, Germany.
12Sigmund-Freud-Str. 25, 53127 Bonn, Germany.
13Meyerhofstraße 1, 69117 Heidelberg, Germany.

* Correspondence: bork@EMBL-Heidelberg.de; wuelle@uni-bonn.de
† Equal contributors

Received: 16 June 2017 Accepted: 16 June 2017
Published online: 29 June 2017

Reference
Fig. 1 Genus and species level differences in PD participants and controls. a NMDS ordination of all samples used in this study, using a Bray–Curtis between-sample distance at genus level. This shows the composition relatedness of samples and that PD samples form a subgroup. Outliers denoted with # took antibiotics in a period of 28–34 days prior to feces sampling. See also Additional file 2 for taxonomic analysis while taking these samples into account. b Genus-level sample composition. c The most significant species or groups of taxa that could not be further classified. Unclassified Prevotella is not significant after multiple testing, but was implied in PD in several studies (see "Discussion"). d Species correlating strongest to PD disease severity (as measured by UPDRS III). Note that after multiple testing correction, these are all q > 0.1.

Fig. 4 Structural equation modeling (SEM). SEM analysis of PD in relation to key correlating bacterial functions and taxa (MSEA = 0, PCLOSE = 0.79, AIC = 59.385). Values on paths and boxes are standardized regression and determination coefficients (R2), respectively. Dashed lines and red colors denote negative relationships. The thickness of lines is proportional to regression coefficients. All relationships are statistically significant (P < 0.05, Additional file 5). AIC Akaike information criterion, MSEA mean square error of approximation, PCLOSE probability of close fit.